MESO Mesoblast Limited

5.38
+0.04  (+1%)
Previous Close 5.34
Open 5.33
Price To Book 1.06
Market Cap 532,567,649
Shares 99,025,241
Volume 2,995
Short Ratio
Av. Daily Volume 44,994

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b Class IV primary endpoint reached 1Q 2018.
MPC-150-IM - Class IV
Chronic heart failure (CHF)
Phase 3 completion of enrollment announced March 29, 2018.
MPC-06-ID
Chronic low back pain
BLA filing due following FDA meeting in April 2019.
MSC-100-IV
acute graft versus host disease (aGVHD) in children
Phase 2 data released August 2016. Partnership required for Phase 3 development.
MPC-300-IV
Rheumatoid arthritis
Phase 3 enrolment to be completed 1Q 2019.
MPC-150-IM - Class 2/3
Heart failure
Phase 2b trial did not meet primary endpoint - November 11, 2018.
MPC-150-IM
End-Stage Heart Failure with LVADs

Latest News

  1. If You Had Bought Mesoblast (ASX:MSB) Stock Five Years Ago, You'd Be Sitting On A 69% Loss, Today
  2. Why Teva Pharmaceutical Industries, Mesoblast, and New Gold Jumped Today
  3. Mesoblast Trades Higher After Heart Failure Cell Therapy Receives Orphan Drug Status
  4. Mesoblast Heart Failure Cell Therapy Receives Orphan Drug Designation From FDA for Prevention of Gastrointestinal Bleeding in Patients With Left Ventricular Assist Devices
  5. High Economic Burden in Children With Steroid Refractory Acute Graft Versus Host Disease
  6. Mesoblast to Host Virtual Symposium With Key Opinion Leader Highlighting Acute Graft Versus Host Disease
  7. Mesoblast and JCR Pharmaceuticals Expand Japan License Agreement to Use of Mesenchymal Stem Cells in Newborns With Insufficient Blood Flow to the Brain
  8. Mesoblast Reports Financial Results and Operational Highlights for the Period Ended March 31, 2019
  9. Mesoblast Starts Rolling BLA Submission for Remestemcel-L
  10. Mesoblast Financial Results Webcast for Period Ended March 31, 2019
  11. Mesoblast Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for remestemcel-L in the Treatment of Acute Graft Versus Host Disease
  12. Mesoblast Keynote Presentations to Feature at 2019 Annual Meeting of the International Society for Cell and Gene Therapy
  13. Mesoblast to Present at 2019 RBC Capital Markets Global Healthcare Conference
  14. What Kind Of Shareholders Own Mesoblast Limited (ASX:MSB)?
  15. FDA Agrees to Rolling Review of Mesoblast’s Biologics License Application for Its Cell Therapy in Children With Steroid-Refractory Acute Graft Versus Host Disease
  16. Should You Be Pleased About The CEO Pay At Mesoblast Limited's (ASX:MSB)
  17. Mesoblast to Present at Upcoming Global Life Sciences Conference in London
  18. Memorandum of Understanding for Confirmatory Trial to Support Marketing Approval of Revascor for Reduction of Gastrointestinal Bleeding in LVAD Patients
  19. Mesoblast Licensee Files for Marketing Approval to Treat Epidermolysis Bullosa
  20. U.S. Healthcare Leader Joseph R. Swedish Appointed Mesoblast Chairman